Literature DB >> 28690314

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.

S Herold1, K Sockel1, C Sayehli2, R Herbst3, U Dührsen4, U Oelschlägel1, A Böttner1, H Hindahl5, J Kullmer6, S Helas1, M Sauer1, B Mohr1, A Mies1, M Bornhäuser1, G Ehninger1, C Röllig1, C Thiede1,7, U Platzbecker1,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28690314     DOI： 10.1038/leu.2017.217

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

Review 1.  Therapy-related acute leukemia.

Authors:  J E Karp; C B Sarkodee-Adoo
Journal:  Clin Lab Med       Date:  2000-03       Impact factor: 1.935

2.  Assessment of Minimal Residual Disease in Standard-Risk AML.

Authors:  Sarah Morin-Zorman; Aline Renneville; Lionel Adès
Journal:  N Engl J Med       Date:  2016-08-11       Impact factor: 91.245

3.  Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.

Authors:  G Metzgeroth; C Walz; J Score; R Siebert; S Schnittger; C Haferlach; H Popp; T Haferlach; P Erben; J Mix; M C Müller; H Beneke; L Müller; F Del Valle; W E Aulitzky; G Wittkowsky; N Schmitz; C Schulte; K Müller-Hermelink; E Hodges; S J Whittaker; F Diecker; H Döhner; P Schuld; R Hehlmann; A Hochhaus; N C P Cross; A Reiter
Journal:  Leukemia       Date:  2007-03-22       Impact factor: 11.528

Review 4.  Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).

Authors:  Toshie Ogasawara; Masako Yasuyama; Kiyotaka Kawauchi
Journal:  Am J Hematol       Date:  2005-06       Impact factor: 10.047

5.  Therapy-related myelodysplastic syndrome/acute myeloid leukemia with del(7)(q22) in a patient with de novo AML.

Authors:  Yang Gyun Kim; Sun Young Cho; Tae Sung Park; Seung Hwan Oh; Hwi-Joong Yoon
Journal:  Ann Clin Lab Sci       Date:  2011       Impact factor: 1.256

6.  Two independent clones in myelodysplastic syndrome following treatment of acute myeloid leukemia.

Authors:  Masahiro Masuya; Naoyuki Katayama; Koichi Inagaki; Hiroshi Miwa; Natsuki Hoshino; Hiroyuki Miyashita; Hirohito Suzuki; Hiroto Araki; Hidetsugu Mitani; Kazuhiro Nishii; Shin-ichi Kageyama; Nobuyuki Minami; Hiroshi Shiku
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

7.  Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.

Authors:  I Lobe; F Rigal-Huguet; A Vekhoff; B Desablens; D Bordessoule; C Mounier; A Ferrant; M Sanz; M Fey; C Chomienne; S Chevret; L Degos; P Fenaux
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

Review 8.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

9.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

10.  Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome.

Authors:  Saba F Ali; Rebecca J Sonu; Denis M Dwyre; Brian A Jonas; Hooman H Rashidi
Journal:  Case Rep Hematol       Date:  2015-12-21
View more
  8 in total

1.  Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.

Authors:  Anne Sophie Kubasch; Rebekka Wehner; Serena Bazzurri; Antje Tunger; Sebastian Stasik; Marlene Garzarolli; Jörn Meinel; Gustavo Baretton; Friedegund Meier; Christian Thiede; Marc Schmitz; Uwe Platzbecker
Journal:  Blood Adv       Date:  2018-06-12

2.  NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.

Authors:  Alexander Höllein; Manja Meggendorfer; Frank Dicker; Sabine Jeromin; Niroshan Nadarajah; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal:  Blood Adv       Date:  2018-11-27

Review 3.  Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia.

Authors:  Robert P Hasserjian; David P Steensma; Timothy A Graubert; Benjamin L Ebert
Journal:  Blood       Date:  2020-05-14       Impact factor: 22.113

4.  2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Michael Heuser; Sylvie D Freeman; Gert J Ossenkoppele; Francesco Buccisano; Christopher S Hourigan; Lok Lam Ngai; Jesse M Tettero; Costa Bachas; Constance Baer; Marie-Christine Béné; Veit Bücklein; Anna Czyz; Barbara Denys; Richard Dillon; Michaela Feuring-Buske; Monica L Guzman; Torsten Haferlach; Lina Han; Julia K Herzig; Jeffrey L Jorgensen; Wolfgang Kern; Marina Y Konopleva; Francis Lacombe; Marta Libura; Agata Majchrzak; Luca Maurillo; Yishai Ofran; Jan Philippe; Adriana Plesa; Claude Preudhomme; Farhad Ravandi; Christophe Roumier; Marion Subklewe; Felicitas Thol; Arjan A van de Loosdrecht; Bert A van der Reijden; Adriano Venditti; Agnieszka Wierzbowska; Peter J M Valk; Brent L Wood; Roland B Walter; Christian Thiede; Konstanze Döhner; Gail J Roboz; Jacqueline Cloos
Journal:  Blood       Date:  2021-12-30       Impact factor: 22.113

Review 5.  Evolutionary trajectory of leukemic clones and its clinical implications.

Authors:  Amos Tuval; Liran I Shlush
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

6.  The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.

Authors:  Jennifer B Dunlap; Jessica Leonard; Mara Rosenberg; Rachel Cook; Richard Press; Guang Fan; Philipp W Raess; Brian J Druker; Elie Traer
Journal:  Am J Hematol       Date:  2019-06-21       Impact factor: 13.265

Review 7.  NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Authors:  Fabio Forghieri; Vincenzo Nasillo; Ambra Paolini; Francesca Bettelli; Valeria Pioli; Davide Giusti; Andrea Gilioli; Corrado Colasante; Gloria Acquaviva; Giovanni Riva; Patrizia Barozzi; Rossana Maffei; Leonardo Potenza; Roberto Marasca; Claudio Fozza; Enrico Tagliafico; Tommaso Trenti; Patrizia Comoli; Giuseppe Longo; Mario Luppi
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

8.  Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns.

Authors:  Tanja Božić; Chao-Chung Kuo; Jan Hapala; Julia Franzen; Monika Eipel; Uwe Platzbecker; Martin Kirschner; Fabian Beier; Edgar Jost; Christian Thiede; Wolfgang Wagner
Journal:  Leukemia       Date:  2021-06-15       Impact factor: 11.528
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.